跳至主要内容
临床试验/NCT01098396
NCT01098396Unknown不适用

Rasagiline for the Treatment of Gait Disturbances in Patients With Parkinson´S Disease (PD): an Open Label Study

Tel-Aviv Sourasky Medical Center0 个研究点目标入组 10 人开始时间: 2010年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
10

研究概览

简要总结

Gait disturbances are very common and are a major cause for losing of independency in patients with advanced Parkinson's Disease (PD). The medical treatment of gait disturbances in advanced PD is very difficult and in many cases the classical dopaminergic treatment has no clinical benefit or even can worsen the instability and increase falls. Rasagiline, a new MAO-B inhibitor who has recently been approved all over the world for the treatment of early and late stages PD has been suggested to have a special effect of gait in patients with advanced PD (LARGO sub-study).

研究设计

研究类型
Observational
观察模型
Case Only

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with PD who experience motor response fluctuations and have gait disturbances at ON and OFF (TUaG >10 secs in ON and 14 secs in OFF) treated with a stable dose of antiparkinsonian medications for the last month. Patients must be able to identify both situations
  • Able to walk for 2 minutes at the OFF and ON state
  • Non-demented (MMSE= or > to25)

排除标准

  • Severe orthopedic problems
  • Orthostatic hypotension on basal visit
  • Severe, troublesome ON dyskinesias
  • Dementia (MMSE <25)
  • Major depression
  • Active psychosis or on anti-psychotic medications
  • Patients who are unlikely to complete the full protocol.
  • Patients who have tried rasagiline and stopped because of side effects or lack of symptomatic effect
  • Treatment with selegiline for the last 2 months
  • Any contraindication according SmPC

研究者

申办方类型
Other Gov

相似试验